Gamma Irradiation Dose Optimization for SARS-CoV-2 Antigen Preservation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing antigens corresponding to SARS-CoV-2 viruses are inefficient due to high doses of gamma radiation required for inactivation, which can destroy the tertiary structure and immunogenic characteristics of the virus, making it unsuitable for use in vaccines or serum therapy.
Innovation Solution
A process involving the cultivation, purification, and gamma irradiation of SARS-CoV-2 viruses using a dose of 15 kGy, which maintains the immunogenicity and biological activity of the antigen, allowing its use in vaccine production and hyperimmune plasma generation for equine immunoglobulins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of gamma radiation are used for virus inactivation, then virus inactivation is achieved, but the tertiary structure and immunogenic characteristics of the virus are destroyed
Solution Approach 1:
The patent applies parameter changes by optimizing the gamma radiation dose from conventional high doses (typically 25-50 kGy) to a lower dose range of 15-25 kGy. This parameter adjustment allows sufficient virus inactivation while preserving the tertiary structure and immunogenic characteristics of the SARS-CoV-2 antigen, resolving the contradiction between complete inactivation and maintaining immunogenicity
Solution Approach 2:
The patent employs partial action by applying a moderate gamma radiation dose that is sufficient for virus inactivation but not excessive enough to destroy the antigen's immunogenic properties. The dose of 15-25 kGy represents a carefully calibrated partial action that achieves the necessary inactivation threshold while stopping before causing structural damage
2Object-affected harmful factors
If gamma irradiation is used for virus inactivation, then virus safety is improved, but the antigen may become unsuitable for vaccine production
Solution Approach 1:
By changing the gamma radiation dose parameter to the optimized range of 15-25 kGy, the patent achieves virus inactivation that maintains antigen suitability for vaccine production. This parameter optimization ensures the antigen retains its immunogenic characteristics while being sufficiently inactivated for safety
Solution Approach 2:
The patent creates a copy of the SARS-CoV-2 virus that has been inactivated by gamma irradiation but retains the essential immunogenic features. The inactivated virus serves as a safe copy that can be used for vaccine production and antibody generation without the risks associated with live virus
3Reliability
If conventional gamma radiation doses are used, then complete virus inactivation is achieved, but the cost and complexity of the process increase
Solution Approach 1:
The patent simplifies the process by establishing a specific gamma radiation dose range of 15-25 kGy that achieves complete virus inactivation without requiring complex additional processing steps. This parameter specification provides a clear, reproducible protocol that reduces process complexity while ensuring reliable inactivation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process effectively inactivates SARS-CoV-2 while preserving its immunogenic properties, enabling the production of safe and effective equine immunoglobulins that can neutralize the virus and reduce disease severity in animal models.
Implementation Method 1
viral inactivation is by gamma irradiation
Data Source
AI summary
The present invention relates to techniques and methods for producing, purifying, inactivating and analyzing SARS-CoV-2. The present invention relates to the method for producing an antigen corresponding to the SARS-COV-2 virus inactivated by gamma radiation. The method for producing an antigen corresponding to the SARS-COV-2 virus inactivated by gamma radiation is intended for use in the production of a novel vaccine, the antigen being used in the production of hyperimmune plasma in horses for serum therapy, and in different animal species for the production of antibodies/research inputs and the establishment of serum diagnosis techniques. The present invention relates to the antigenic composition including the antigen corresponding to the inactivated SARS-COV-2 virus and a pharmaceutically acceptable diluent excipient. The invention also relates to a method for producing anti-SARS-CoV-2 immunoglobulins using the SARS-COV-2 virus inactivated by gamma radiation.